Fetcroja 1 g powder for concentrate for solution for infusion

DRUG3 trials

Sponsors

Shionogi B.V., Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla, Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico

Conditions

Aerobic Gram-negative bacterial infectionsBacteriemia producida por P. aeruginosa.Patients colonized with CPE undergoing liver transplantation (LT)

Phase 2

A multicenter, single-arm, open-label study to assess the pharmacokinetics, safety, and tolerability of cefiderocol in hospitalized pediatric patients from birth to < 3 months of age with suspected or confirmed aerobic Gram-negative bacterial infections

WithdrawnCTIS2023-503757-35-00

Shionogi B.V.Aerobic Gram-negative bacterial infections

Target: 20Updated: 2023-10-30

Phase 3

Targeted versus standard peri-operative prophylaxis in patients colonized with carbapenemase-producing Enterobacterales undergoing liver transplantation: a stepped-wedge cluster randomization trial

Not yet recruitingCTIS2025-523453-34-00

Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere ScientificoPatients colonized with CPE undergoing liver transplantation (LT)

Target: 168Updated: 2026-08-31

Phase 4

Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized (SHORTEN-2) clinical trial with a DOOR/RADAR analysis.

Not yet recruitingCTIS2023-508441-41-00

Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De SevillaBacteriemia producida por P. aeruginosa.

Target: 306Updated: 2025-07-25